Zentalis Pharmaceuticals, Inc.
ZNTL
$1.62
-$0.015-0.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -31.04% | -73.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.72% | -48.17% | |||
| Operating Income | 7.72% | 17.97% | |||
| Income Before Tax | 44.34% | -1.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 44.34% | -1.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 44.34% | -1.70% | |||
| EBIT | 7.72% | 17.97% | |||
| EBITDA | 7.50% | 17.97% | |||
| EPS Basic | 44.58% | -1.13% | |||
| Normalized Basic EPS | 32.29% | 47.82% | |||
| EPS Diluted | 44.58% | -1.13% | |||
| Normalized Diluted EPS | 32.29% | 47.82% | |||
| Average Basic Shares Outstanding | 0.44% | 0.57% | |||
| Average Diluted Shares Outstanding | 0.44% | 0.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||